CLGN Share Price Performance
US$0.42
-1.23 (-74.56%)
96.5% undervalued intrinsic discount
US$12.00
Fair Value
Price US$0.42
AnalystConsensusTarget US$12.00
Fair ValueUS$11.56
Share Pricen/a
CollPlant Biotechnologies Ltd. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
CLGN Community Narratives
AN
Fair Value
·Fair Value US$11.56 96.4% undervalued intrinsic discount
Expanding Distribution And Pipeline Advances Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Expanding Distribution And Pipeline Advances Will Open New Markets
Key Takeaways Expanding distribution channels and promising product development are poised to drive future revenue growth and market potential. Strategic collaborations and innovative technologies could unlock significant revenue opportunities and milestone payments.Read more
AN
US$11.56
96.4% undervalued intrinsic discount
Fair Value
Profit Margin
16.06%
Future PE
88.19x
Price in 2028
US$12.67
Trending Discussion
Recently Updated Narratives
AN
Expanding Distribution And Pipeline Advances Will Open New Markets
Fair Value: US$11.56 96.4% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CollPlant Biotechnologies Ltd. Key Details
About CLGN
- Founded
- 2004
- Employees
- 39
- CEO
- WebsiteView website
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
